AChE inhibitors such as Tacrine, Donepezil, Rivastigmine, Galantamine, and the N-methyl-D-aspartate (NMDA) receptor antagonist Memantine have been approved by the Food and Drug Administration for AD management [3,4,14,15]. Here, ACHE is linked to Alzheimer disease.